Vimta Labs Limited has released the transcript of its Q4 and FY '26 Earnings and Investor Call held on 06 May 2026, filed with BSE Limited and the National Stock Exchange of India Limited under reference VLL\SE\015\2026-27 dated 12 May 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call was hosted by Systematix Institutional Equities and featured senior management including Managing Director Ms. Harita Vasireddi, Executive Director Mr. Satya Sreenivas Neerukonda, CFO Mr. Siva Rama Krishna, and Company Secretary Ms. Sujani Vasireddi. The transcript, along with the audio recording, is available on the company's official website at https://vimta.com/investor-earnings-call/ .

FY '26 Business Overview

Addressing participants, Managing Director Harita Vasireddi described FY '26 as "a year of strong execution, resilience, and strategic progress." Pharmaceutical research and testing services remained the largest revenue contributor, driven by demand from both domestic and international customers, while food testing demonstrated strong momentum. Electronics and electrical testing as well as environmental testing continued to scale in line with expectations. The company successfully underwent multiple regulatory and customer audits during the year, reinforcing its compliance credentials. Vimta also marked a strategic milestone with its entry into biologics contract research and development services, with infrastructure, people, systems, and equipment fully in place as the company prepares to build traction in FY '27.

Q4 and Full-Year Financial Performance

CFO Siva Rama Krishna presented the financial highlights for the quarter and full year ended 31 March 2026. The following tables summarise the key metrics:

Krishna noted that the strong Q4 performance was primarily driven by the pre-clinical and food testing divisions. He also highlighted that the company maintains a net debt-free balance sheet with cash and cash equivalents, including bank balances, of close to INR650 million. Export revenues accounted for approximately 38% of Q4 revenues. Following the divestment of the diagnostic and pathological services business in 2024, prior period figures have been regrouped for like-to-like comparison.

Growth Drivers and Industry Outlook

Management elaborated on the key growth drivers across its service verticals during the Q&A session. Harita Vasireddi noted that outsourcing in contract research and testing—spanning pharmaceuticals, food, electronics, and nutraceuticals—continues to grow, with the underlying industries expanding at rates of 7% to 12% globally. She highlighted that the shift in pharmaceutical R&D pipelines from small molecules to large molecules is driving increased innovation activity, and that India's Atmanirbhar initiative is boosting electronics testing demand, particularly in Hyderabad, which is a hub for defence OEMs. On the Indian analytical testing market, management indicated it is estimated to reach approximately USD300 million by 2030, which remains small relative to the global pharma analytical testing industry size of approximately USD9.70 billion.

On the impact of geopolitical developments, management acknowledged a slight increase in input material and consumable costs and marginally longer supply chain lead times. The pharmaceutical industry experienced some strain due to US tariffs, which have since been reversed. Food testing saw an impact in the last fortnight of March due to disruptions affecting exporters and import testing at the NFL in Navi Mumbai. Management also noted that on the revenue target front, the company had originally aimed to reach INR500 crore run rates, and while some external headwinds affected Q4, management expressed confidence in maintaining growth momentum going forward.

Segment Updates

Management provided specific updates across key service lines during the investor Q&A. On electronics and electrical testing, Vasireddi acknowledged that the segment did not achieve the momentum anticipated, citing leadership challenges on both the operational and business development sides, which have since been resolved. Despite these challenges, the team retained most customers and maintained strong word-of-mouth in the region. On environmental testing, the company has transitioned away from environmental impact assessment (EIA) and is now focused solely on post-project monitoring (PPM), with management noting this is not a high-focus area given limited growth opportunities in the segment. On the revenue mix, fee-for-service (FFS) constitutes the dominant portion of revenues, with full-time equivalent (FTE) arrangements limited to analytical services within the pharma segment.

Biologics, New Capacity, and Strategic Initiatives

Management confirmed that the biologics contract research and development vertical is ready to commence operations in FY '27, with all infrastructure, equipment, and personnel in place. The company is in active discussions with prospective clients from Europe, India, and the US, with finalisation of product and modality underway. On margins for the biologics business, management indicated expectations are broadly in line with the core testing business, with early-stage projects likely to be domestic-led before the company pursues overseas clients for potentially higher margins.

Vimta also disclosed the approval of a subsidiary in the United States, the primary purpose of which is to be closer to its customer base and enhance confidence among US-based clients. Management clarified that the subsidiary does not provide a meaningful tariff advantage, as tariffs have limited impact on the services the company provides. On capital allocation, management stated there are no current plans for equity issuance or acquisitions, while noting that the new facility is designed to support growth over the next four to five years, with utilisation expected to ramp up progressively.

Disclosure Details

The filing was signed by Sujani Vasireddi, Company Secretary and Compliance Officer, and submitted to both BSE Limited and the National Stock Exchange of India Limited. The key disclosure parameters are as follows:

Vimta Labs has reported its audited financial results for the fourth quarter and full year ended March 31, 2026, with the Board meeting held on May 06, 2026. The company delivered robust growth across key metrics, with standalone net profit (PAT) for Q4 FY26 rising to ₹211.13 million from ₹183.19 million in the year-ago quarter, marking a 15.2% year-on-year increase. Revenue from operations for the quarter stood at ₹1,092.45 million, up significantly from ₹944.41 million in Q4 FY25. Beyond the financial results, the Board approved several strategic and governance actions, including the incorporation of a wholly owned subsidiary in the USA.

Key Financial Highlights

The company's performance showed improvement across all major metrics on both a year-on-year and quarter-on-quarter basis. The following table summarizes the key financial figures:

For the full fiscal year FY26, Total Income reached ₹4,162.79 million, up 19.50% from ₹3,482.22 million in FY25. Net Profit for the year increased to ₹775.12 million from ₹667.55 million in FY25 (from continuing operations). Basic EPS from continuing operations stood at 17.40 INR, while Diluted EPS stood at 17.20 INR for FY26.

Operational Efficiency and Balance Sheet Strength

Vimta Labs posted EBITDA of ₹421 million for Q4 FY26, reflecting strong operational efficiency. The EBITDA margin expanded to 37.60% from 36.10% in the year-ago quarter and 34.30% in Q3 FY26. Total expenses for Q4 FY26 stood at ₹829.49 million, compared to ₹710.54 million in Q4 FY25. The company's balance sheet as of March 31, 2026 reflects a healthy financial position, as detailed below:

Net cash flows generated from operating activities for the year ended March 31, 2026 stood at ₹1,471.42 million, compared to ₹940.54 million in the prior year. Net cash used in investing activities was ₹1,296.68 million, primarily driven by payments for property, plant and equipment and capital work-in-progress of ₹996.80 million. Cash and cash equivalents at the end of the year stood at ₹229.69 million.

Corporate Actions and Strategic Developments

The Board approved several significant actions at its meeting. The following table summarizes the key corporate decisions:

The dividend recommendation and the reappointment of Dr. S. P. Vasireddi as Executive Chairman are subject to shareholder approval at the ensuing Annual General Meeting. Additional information regarding the US subsidiary incorporation, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, will be disclosed in due course.

Bonus Shares and ESOP

Pursuant to shareholder approval at the 35th Annual General Meeting held on June 06, 2025, the company issued bonus shares in the ratio of 1:1, allotting 2,22,52,784 equity shares on June 14, 2025 to shareholders on record as of June 13, 2025. Consequently, ₹44.51 million (representing par value of ₹2 per share) was transferred from Securities Premium to the Share Capital Account. Earnings per share for all prior periods have been proportionately adjusted. Regarding the Employee Stock Option Plan (ESOP), the company applied to the stock exchanges for in-principle approval of 5,18,260 ESOP grants arising from the bonus issue, receiving approvals from BSE on August 29, 2025 and from NSE on September 01, 2025. The company operates in a single reportable segment, namely 'Contract Research and Testing Services', as assessed under Ind AS-108. The audited financial results carry an unmodified opinion from statutory auditors M/s Gattamaneni & Co., Chartered Accountants.